Abstract:
The present application relates to solid state forms, for example, crystalline forms of 2'- C-methyluridine-5 '-(O-phenyl-N-(S)- 1 -(isopropoxycarbonyl)ethyl)thiophosphoramidate, pharmaceutical compositions that can include one or more solid forms of 2'-C-methyluridine-5'- (0-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, and methods of treating or ameliorating diseases and/or conditions with one or more solid forms of 2'-C-methyluridine-5'- (O-phenyl-N-(S)- 1 -(isopropoxy carbonyl)ethyl)thiophosphoramidate. Also disclosed herein are methods of treating diseases and/or conditions with one or more solid forms of 2'-C- methyluridine-5 '-(O-phenyl-N-(S)- 1 -(isopropoxycarbonyl)ethyl)thiophosphoramidate in combination with one or more other agents.
Abstract:
Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide are described herein, including crystalline forms thereof.
Abstract:
Co-cristales que comprenden un compuesto derivado de quinolina-2carboxamida de fórmula (I) y un formador de cristales; composiciones que los comprenden; método de preparación de los co-cristales y uso de estos en la preparación de un medicamento útil para el tratamiento de cáncer
Abstract:
The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith.